MedTrace Logo

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

NCT05177107 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-08-19

No results posted yet for this study

Summary

This is a phase 2b randomized trial designed to evaluate bacteriophage therapy in subjects with diabetic foot osteomyelitis.

Conditions

  • Osteomyelitis
  • Diabetic Foot Osteomyelitis

Interventions

BIOLOGICAL

Bacteriophage Therapy

Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

OTHER

Placebo

Placebo (normal saline)

Sponsors & Collaborators

  • Adaptive Phage Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nitsan Halevy, MD · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-24
Primary Completion
2025-01-30
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177107 on ClinicalTrials.gov